sigma-aldrich (SIAL) Key Developments
BioReliance Licenses B-CLEAR Technology from Qualyst Transporter Solutions for Drug Transporter Studies
Apr 22 15
BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business under SAFC Commercial announced a non-exclusive license agreement with Qualyst Transporter Solutions for its proprietary B-CLEAR technology. Used in conjunction with BioReliance technologies, B-CLEAR enables researchers to assess drug disposition and drug interactions within complex, whole-cell liver systems. When applied to properly functioning hepatic cells, B-CLEAR opens the bile pockets (analogous to bile canaliculi in vivo), allowing material that has been transported from inside the cell into the bile pocket to be measured. The efflux measurements can then facilitate evaluation of biliary clearance, transporter interactions and intracellular concentration. Until now, the study of the individual role of a transporter in primary hepatocytes and HepaRG cells, which express all of the hepatic transporters, was very difficult. However, by using Sigma-Aldrich CompoZr Zinc Finger Nuclease (ZFN) technology, HepaRG transporter knockout cell lines have been created empowering more accurate research investigations of liver transporters. The B-CLEAR technology enables effective measurement of uptake and efflux into the bile pocket, and the overall integrated effect of transporters and metabolism can also be evaluated.
Sigma-Aldrich Opens New Cell Culture Technical Center in Singapore
Apr 21 15
Sigma-Aldrich Corporation has opened its Asia Pacific headquarters and cell culture technical center in Singapore. Located at Biopolis Research Park, the facility will provide customized support to meet customer needs, leveraging the company's scientific capabilities. The facility brings existing commercial offices and production laboratories in Singapore into a single location, together with the new Cell Culture Technical Center. The Technical Center will primarily support the customers of SAFC Commercial business in biopharmaceutical development and manufacturing. The Cell Culture Technical Center is designed to address a wide range of needs of customers in the Asia region, ranging from development projects, product support, trouble-shooting and application issues. Expected to open at the end of this year, the distribution center will enable Sigma-Aldrich to provide end-to-end services to its customers and distributors in Singapore and across South East Asia (SEA).
Sigma-Aldrich Corp to Opens Asia Pacific Headquarters and a New Distribution Center in Tuas
Apr 17 15
Sigma-Aldrich Corp. is expanding its investment in the Asia Pacific region, opening a new headquarters and cell culture center in Singapore as well as a new distribution center in Tuas. The company's new Asia Pacific HQ and cell culture technical center are located in Singapore's Biopolis Research Park. The new HQ facility brings existing commercial office and production laboratories in Singapore into one central location, according to a statement from the company. The cell culture technical center will support customers in Sigma-Aldirch's SAFC commercial business in biopharmaceutical development and manufacturing. Sigma-Aldrich also plans to construct its own distribution center in Tuas, which will be the company's first full-owned distribution center in South East Asia. The center is expected to be open at the end of the year.
SAFC Commercial Launches New EX-CELL® Advanced(TM) Products for Scalable, Efficient Biopharmaceutical Manufacturing
Apr 17 15
SAFC Commercial launched the EX-CELL® Advanced™ product line. Designed to address the needs of an evolving industry where speed to market is paramount, the new product line provides for increased performance, streamlines regulatory compliance, and offers the supply chain security needed in today's biopharmaceutical environment. The first EX-CELL Advanced product is the high-performing batch media system developed for a range of widely used industrial CHO cell lines, including SAFC's proprietary CHOZN® cell line. During rigorous testing, the EX-CELL Advanced CHO Fed-batch System outperformed other commercially available equivalents by displaying significantly higher titers. Robust scale up and effortless adaptation offers those in biopharmaceutical development the opportunity to get their process up and running quickly and efficiently. Protein quality, another vital consideration in the development process, remains uncompromised.
Eric M. Green to Resign as Executive Vice President and President of Sigma-Aldrich Corporation's Research Business Unit, Effective April 23, 2015
Apr 15 15
On April 13, 2015, Eric M. Green, Executive Vice President and President of the Research Business Unit, notified Sigma-Aldrich Corporation that he will resign from the company, effective April 23, 2015. Dr. Frank Wicks will take over leadership of the Research Business Unit in addition to his duties as President of the Applied Business Unit.